Figg W - Search Results

1

Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization.

Levy EB, Peer C, Sissung TM, Venkatesan A, Pandalai P, Greten T, Hughes MS, Garcia C, Peretti J, Figg W, Lewis A, Wood B. Levy EB, et al. Among authors: figg w. J Vasc Interv Radiol. 2019 Jan;30(1):19-22. doi: 10.1016/j.jvir.2018.06.023. Epub 2018 Dec 6. J Vasc Interv Radiol. 2019. PMID: 30527657 Free PMC article.

2

Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies.

Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD, Zhai S, Beresneva T, Seidel GD, Alexander HR. Pingpank JF, et al. Among authors: figg wd. J Clin Oncol. 2005 May 20;23(15):3465-74. doi: 10.1200/JCO.2005.00.927. J Clin Oncol. 2005. PMID: 15908655 Free PMC article. Clinical Trial.

3

Effect of ABCG2 genotype on the oral bioavailability of topotecan.

Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, Gelderblom H. Sparreboom A, et al. Cancer Biol Ther. 2005 Jun;4(6):650-8. doi: 10.4161/cbt.4.6.1731. Epub 2005 Jun 11. Cancer Biol Ther. 2005. PMID: 15908806

4

Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention.

Sissung TM, Price DK, Sparreboom A, Figg WD. Sissung TM, et al. Mol Cancer Res. 2006 Mar;4(3):135-50. doi: 10.1158/1541-7786.MCR-05-0101. Mol Cancer Res. 2006. PMID: 16547151 Review.

5

Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.

Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S. Sissung TM, et al. Eur J Cancer. 2006 Nov;42(17):2893-6. doi: 10.1016/j.ejca.2006.06.017. Epub 2006 Sep 6. Eur J Cancer. 2006. PMID: 16950614 Free PMC article.

6

Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.

Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W. Figg WD, et al. BJU Int. 2007 May;99(5):1047-55. doi: 10.1111/j.1464-410X.2007.06763.x. BJU Int. 2007. PMID: 17437439 Clinical Trial.

7

CYP2D6 polymorphisms and the impact on tamoxifen therapy.

Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD. Beverage JN, et al. J Pharm Sci. 2007 Sep;96(9):2224-31. doi: 10.1002/jps.20892. J Pharm Sci. 2007. PMID: 17518364 Review.

8

Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.

Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D, Sparreboom A, Dahut WL, Figg WD. Hamada A, et al. Urology. 2007 Aug;70(2):217-20. doi: 10.1016/j.urology.2007.06.1097. Urology. 2007. PMID: 17826473 Free PMC article.

9

Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.

Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A. Sissung TM, et al. Mol Cancer Ther. 2008 Jan;7(1):19-26. doi: 10.1158/1535-7163.MCT-07-0557. Epub 2008 Jan 9. Mol Cancer Ther. 2008. PMID: 18187806

10

Genetic stability of tumor microenvironment.

Danish M, Sissung T, Price DK, Figg WD. Danish M, et al. Cancer Biol Ther. 2008 Mar;7(3):331-2. doi: 10.4161/cbt.7.3.5761. Epub 2008 Feb 20. Cancer Biol Ther. 2008. PMID: 18362517 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

784 results

Search Page